EUVIMEDEUVIMED entdecken
Crossref

Administrating Everolimus against neuroendocrine differentiated prostate cancer, a preliminary experience

Tatsuya Shimomura, Masaya Murakami, Kanako Kasai, Yu Imai, Yuzo Inaba, Takahiro Kimura

Canadian Journal of Urology · 2026 · 33 (5) · 1179-1185

DOI: 10.32604/cju.2026.076841 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Canadian Journal of Urology, 2026. Verfasst von Tatsuya Shimomura und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Everolimus, Prostatic Neoplasms, Antineoplastic Agents.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Neuroendocrine prostate cancer (NEPC) is a deadly condition, with a median overall survival of less than one year after diagnosis. Although clinical trials are ongoing, an established treatment strategy for NEPC has not yet been developed. A recent clinical trial, RADIANT-4, showed that treatment with everolimus significantly improved survival in patients with progressive neuroendocrine tumors of the lung or gastrointestinal tract. This study evaluated the efficacy of everolimus against neuroendocrine differentiated prostate cancer as an initial investigation. METHODS: Five patients with neuroendocrine differentiated prostate cancer were treated with everolimus (10 mg daily). In our study, we examined the responses and changes over time of circulating neuroendocrine tumor markers, including neuron-specific enolase (NSE) and pro-gastrin-releasing peptide (pro-GRP). We also evaluated survival outcomes such as castration-resistant prostate cancer (CRPC)-free survival, overall survival (OS), and cancer-specific survival (CSS). RESULTS: The median follow-up duration was 32 months. A decline in circulating neuroendocrine tumor markers was observed in all cases. The median decline rate of NSE was -0.417, and that of pro-GRP was -0.647 (p = 0.841). The median CRPC-free survival was 10 months (range: 3-NA). Median CSS and OS were both 32 months (range: 8-NA). Grade 3 adverse events (AEs) included hyperglycemia and pneumonitis. Grade 1 AEs included stomatitis (2 cases), paronychia, and pneumonitis. CONCLUSIONS: Everolimus demonstrated reductions in circulating neuroendocrine markers in this exploratory cohort of prostate adenocarcinoma with neuroendocrine differentiation; however, these findings are descriptive and do not establish treatment efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EverolimusProstatic NeoplasmsAntineoplastic AgentsHumansMalePhosphopyruvate HydrataseAgedBiomarkers, TumorMiddle AgedPeptide Fragments

Stichwörter der Autor:innen

everolimusneuroendocrine differentiationneuroendocrine tumor markersneuron-specific enolasepro-gastrin-releasing peptideprostate cancer

Substanzen

EverolimusPhosphopyruvate HydrataseAntineoplastic AgentsBiomarkers, TumorPeptide Fragments

Autor:innen und Institutionen

  • Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
  • Department of Urology, Fuji City General Hospital, Fuji, Japan.

Zitieren

APA

Shimomura, T., Murakami, M., Kasai, K., Imai, Y., Inaba, Y., & Kimura, T. (2026). Administrating Everolimus against neuroendocrine differentiated prostate cancer, a preliminary experience. Canadian Journal of Urology, 33(5), 1179-1185. https://doi.org/10.32604/cju.2026.076841

Vancouver

Shimomura T, Murakami M, Kasai K, Imai Y, Inaba Y, Kimura T. Administrating Everolimus against neuroendocrine differentiated prostate cancer, a preliminary experience. Canadian Journal of Urology. 2026;33(5):1179-1185. doi:10.32604/cju.2026.076841

BibTeX
@article{Shimomura2026,
  author = {Shimomura, Tatsuya and Murakami, Masaya and Kasai, Kanako and Imai, Yu and Inaba, Yuzo and Kimura, Takahiro},
  title = {Administrating Everolimus against neuroendocrine differentiated prostate cancer, a preliminary experience},
  journal = {Canadian Journal of Urology},
  year = {2026},
  volume = {33},
  number = {5},
  pages = {1179--1185},
  doi = {10.32604/cju.2026.076841}
}
Kostenlos starten →